Paired Tissue and Plasma Comprehensive Genomic Profiling in Advanced Solid Tumors: A Retrospective Study from India.
- 1Medical Oncology Department, Fortis Memorial Research Institute, Gurugram 122003, India.
- 2Department of Medical Affairs, Guardant Health India Pvt. Ltd., Hyderabad 500032, India.
- 3Department of Medical Affairs, Guardant Health Pte Ltd., Singapore 138567, Singapore.
Abstract
Background
Tissue and plasma comprehensive genomic profiling (CGP) sample different compartments and may yield nonoverlapping clinically relevant findings. We assessed the added patient-level yield of paired testing in a pan-cancer cohort from India.Methods
This retrospective, single-institution study included patients with stage IV solid tumors who underwent paired tissue and plasma CGP between November 2022 and October 2024. The primary endpoint was detection in a patient of an OncoKB Level 1 or Level 2 or R1 alteration, high tumor mutational burden, or microsatellite instability. Molecularly informed therapy and laboratory turnaround time were assessed descriptively.Results
Of 158 patients, 123 matched evaluable pairs were analyzed. Either modality detected a clinically relevant finding in 46 of 123 patients (37.4%; 95% confidence interval, 29.4-46.2%): tissue CGP in 33 (26.8%), plasma CGP in 35 (28.5%), both in 22 (17.9%), tissue only in 11 (8.9%) and plasma only in 13 (10.6%). This complementarity remained bidirectional across exploratory analyses, including a subgroup that excluded non-small cell lung cancer (33.0%), all 139 technically successful pairs (33.8%), all 158 paired sample sets (32.3%), and even when the endpoint was restricted to OncoKB alterations (22.0%). Among 91 patients with therapy-alignment data, 25 (27.5%) received molecularly informed therapy. Median laboratory turnaround time was 7 days for plasma and 13 days for tissue CGP.Conclusions
Tissue and plasma CGP were complementary rather than interchangeable in this selected cohort: either modality alone would have missed clinically relevant findings. Whether this improves outcomes is untested; prospective studies linking testing strategy to treatment delivery and survival are needed.
Related
- Comprehensive Molecular Profiling for Precision Diagnostics: Integrating Genomic, Proteomic, and Epigenetic Landscapes in Human Pathology
- Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
- Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer
- Comprehensive Genomic Profiling of Relapsed Interdigitating Dendritic Cell Sarcoma Reveals Novel Molecular Insights in a Patient Achieving Durable Remission After Autologous Stem Cell Transplantation
- Incidental MSH6 Germline Pathogenic Variant Identified through Tumor-only Comprehensive Genomic Profiling in a Patient with Small Cell Lung Cancer
BibTeX
@article{bahl2026paired,
title = {{Paired Tissue and Plasma Comprehensive Genomic Profiling in Advanced Solid Tumors: A Retrospective Study from India.}},
author = {Ankur Bahl and Nitesh Rohatgi and Suman S Karanth and Aakriti Aggarwal and Rohit Bharat and Nippun Sandhir},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = sep,
doi = {10.3390/curroncol33100575},
url = {https://europepmc.org/article/MED/42930142},
note = {CC BY},
}
RIS
TY - JOUR
TI - Paired Tissue and Plasma Comprehensive Genomic Profiling in Advanced Solid Tumors: A Retrospective Study from India.
AU - Ankur Bahl
AU - Nitesh Rohatgi
AU - Suman S Karanth
AU - Aakriti Aggarwal
AU - Rohit Bharat
AU - Nippun Sandhir
PY - 2026
DA - 2026/09/25
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100575
UR - https://europepmc.org/article/MED/42930142
AB - Background Tissue and plasma comprehensive genomic profiling (CGP) sample different compartments and may yield nonoverlapping clinically relevant findings. We assessed the added patient-level yield of paired testing in a pan-cancer cohort from India.Methods This retrospective, single-institution study included patients with stage IV solid tumors who underwent paired tissue and plasma CGP between November 2022 and October 2024. The primary endpoint was detection in a patient of an OncoKB Level 1 or Level 2 or R1 alteration, high tumor mutational burden, or microsatellite instability. Molecularly informed therapy and laboratory turnaround time were assessed descriptively.Results Of 158 patients, 123 matched evaluable pairs were analyzed. Either modality detected a clinically relevant finding in 46 of 123 patients (37.4%; 95% confidence interval, 29.4-46.2%): tissue CGP in 33 (26.8%), plasma CGP in 35 (28.5%), both in 22 (17.9%), tissue only in 11 (8.9%) and plasma only in 13 (10.6%). This complementarity remained bidirectional across exploratory analyses, including a subgroup that excluded non-small cell lung cancer (33.0%), all 139 technically successful pairs (33.8%), all 158 paired sample sets (32.3%), and even when the endpoint was restricted to OncoKB alterations (22.0%). Among 91 patients with therapy-alignment data, 25 (27.5%) received molecularly informed therapy. Median laboratory turnaround time was 7 days for plasma and 13 days for tissue CGP.Conclusions Tissue and plasma CGP were complementary rather than interchangeable in this selected cohort: either modality alone would have missed clinically relevant findings. Whether this improves outcomes is untested; prospective studies linking testing strategy to treatment delivery and survival are needed.
SN - 1198-0052
SN - 1718-7729
ER -